Any comments on this new partnership? For what it's worth, slide six of the presentation providing details of the ARRY-Oncothyreon partnership and ARRY-380 Phase I testing results sure impresses me. 100% of patients who got both Herceptin and ARRY-380 had complete responses, and they remained tumor-free for more than 50 days. Nice! Is there any way to figure out how many women got both Herceptin and ARRY-380?